{"disease":{"id":"solid-neoplasms","name":"solid neoplasms"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05847855","title":"Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04264767","title":"Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Nucleix Ltd.","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06431594","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":385,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":344,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03742895","title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":326,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06339541","title":"The ACC Preclinical Research Platform for Precision Oncology","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT04420884","title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03760952","title":"Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Immatics US, Inc.","has_results":false},{"nct_id":"NCT02632448","title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Esperas Pharma Inc.","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03396445","title":"Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04673942","title":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"EpicentRx, Inc.","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT06613295","title":"Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Cancer Research Antwerp","has_results":false},{"nct_id":"NCT04078295","title":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03087227","title":"Shared Health Information System for Febrile Neutropenia","phase":"NA","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Marie-Helene METZGER","has_results":false},{"nct_id":"NCT05103358","title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":false},{"nct_id":"NCT06788509","title":"A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04222413","title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04189445","title":"Futibatinib in Patients With Specific FGFR Aberrations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00670488","title":"Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05512377","title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02829099","title":"A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT04200963","title":"A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04151186","title":"A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"suhaichuan","has_results":false},{"nct_id":"NCT03833700","title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT05514444","title":"Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04572451","title":"Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Yana Najjar","has_results":false},{"nct_id":"NCT07071103","title":"Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT01393509","title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04407676","title":"Improving Informed Consent for Early Phase Anti-Cancer Trials","phase":"NA","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT01519817","title":"Cancer Vaccine Targeting Brachyury Protein in Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03782467","title":"Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Alligator Bioscience AB","has_results":false},{"nct_id":"NCT03364049","title":"Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04991506","title":"A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Elpiscience Biopharma, Ltd.","has_results":false},{"nct_id":"NCT04144842","title":"Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Alligator Bioscience AB","has_results":false},{"nct_id":"NCT06264921","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04009460","title":"A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Elpiscience Biopharma, Ltd.","has_results":false},{"nct_id":"NCT06837090","title":"Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT05432232","title":"The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"HistoSonics, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}